Targeted Molecules Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$320K
Targeted Molecules General Information
Description
Developer of drug therapies for cancer and diseases of the central nervous system. The company's technology enables both the identification and optimization of molecules (peptides and antibody fragments) that precisely target disease tissue.
Contact Information
Website
www.targetedmolecules.comCorporate Office
- 3030 Bunker Hill Street
- Suite 100
- San Diego, CA 92109
- United States
Corporate Office
- 3030 Bunker Hill Street
- Suite 100
- San Diego, CA 92109
- United States
Targeted Molecules Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC | 11-Jul-2005 | $320K | Completed | Product Development | ||
| 4. Merger/Acquisition | 25-May-2005 | Completed | Product Development | |||
| 3. Early Stage VC | 15-Feb-2005 | Completed | Product Development | |||
| 2. Early Stage VC | 11-Sep-2003 | $4M | $14M | Completed | Product Development | |
| 1. Early Stage VC (Series B) | 01-Dec-2001 | $10M | $10M | Completed | Generating Revenue |
Targeted Molecules Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Targeted Molecules Patents
Targeted Molecules Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20040110681-A1 | Generating library of peptides comprising gene expressing oligonucleotides encoding cyclic peptides with randomized coding sequences representing the non-bridging amino acids; treating neuroinflammatory, blood, and lung disorders | Inactive | 08-Aug-2002 | ||
| AU-2003264030-A1 | Improved method to identify targeting molecules | Inactive | 08-Aug-2002 | ||
| AU-2003264030-A8 | Improved method to identify targeting molecules | Inactive | 08-Aug-2002 | ||
| CA-2494551-A1 | Improved method to identify targeting molecules | Inactive | 08-Aug-2002 | ||
| EP-1542733-A2 | Improved method to identify targeting molecules | Inactive | 08-Aug-2002 | C07K7/06 |
Targeted Molecules Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| FAT Capital Management | Venture Capital | Minority | ||
| GC&H Investments | Corporate Venture Capital | Minority | ||
| GeneChem | Venture Capital | Minority | ||
| IngleWood Ventures | Venture Capital | Minority | ||
| Linkagene | Venture Capital | Minority |
Targeted Molecules FAQs
-
When was Targeted Molecules founded?
Targeted Molecules was founded in 2000.
-
Where is Targeted Molecules headquartered?
Targeted Molecules is headquartered in San Diego, CA.
-
What industry is Targeted Molecules in?
Targeted Molecules’s primary industry is Drug Discovery.
-
Is Targeted Molecules a private or public company?
Targeted Molecules is a Private company.
-
What is Targeted Molecules’s current revenue?
The current revenue for Targeted Molecules is .
-
How much funding has Targeted Molecules raised over time?
Targeted Molecules has raised $320K.
-
Who are Targeted Molecules’s investors?
FAT Capital Management, GC&H Investments, GeneChem, IngleWood Ventures, and Linkagene are 5 of 7 investors who have invested in Targeted Molecules.
-
When was Targeted Molecules acquired?
Targeted Molecules was acquired on 11-Jul-2005.
-
Who acquired Targeted Molecules?
Targeted Molecules was acquired by Chromos Molecular Systems.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
